On July 2, Everest Medicines rose 8.16% in regular trading, reaching HK$25.8 with turnover of approximately HK$50.33 million.

The rally was driven by a confluence of positive developments. Most notably, NMPA formally accepted the Biologics License Application for the company's third-generation PCSK9 inhibitor lerodalcibep, targeting LDL-C reduction in adult hypercholesterolemia patients, with potential approval as early as next year. Global Phase III data demonstrated a 65.9% LDL-C reduction, positioning it as a potential best-in-class therapy.

Additionally, the company announced a commercialization partnership with Hainan Herui for budesonide enteric capsules, strengthening its nephrology franchise. These developments follow a series of recent catalysts including the landmark out-licensing of civorebrutinib to Travere Therapeutics for US$112.5 million upfront, the DMX-200 licensing deal with Dimerix, and sustained share purchases by major shareholder CBC Group totaling over HK$172.5 million since December. Multiple brokerages maintain buy ratings, with CICC setting a target price of HK$41.5.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)